Fibroblast growth factor-21 is positively associated with atrial fibrosis in atrial fibrillation patients with rheumatic heart disease

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 11, 2015, Pages 14901-14908

  Wang, Rui ^a   Yi, Xin ^a,b   Li, Xiaoyan ^a,b   Jiang, Xuejun ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Atrial fibrillation; Atrial fibrosis; Fibroblast growth factor 21; Rheumatic heart disease

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21;

ADULT; AGED; ATRIAL FIBRILLATION; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSIS; HEART ATRIUM; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATIC HEART DISEASE;

ADULT; AGED; ATRIAL FIBRILLATION; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; FIBROSIS; HEART ATRIA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RHEUMATIC HEART DISEASE;

EID: 85013489156     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Shiran A and Sagie A. Tricuspid regurgitation in mitral valve disease incidence, prognostic implications, mechanism, and management. J Am Coll Cardiol 2009; 53: 401-408
2. Patel NJ, Patel A, Agnihotri K, Pau D, Patel S, Thakkar B, Nalluri N, Asti D, Kanotra R, Kadavath S, Arora S, Patel N, Patel A, Sheikh A, Patel N, Badheka AO, Deshmukh A, Paydak H and Viles-Gonzalez J. Prognostic impact of atrial fibrillation on clinical outcomes of acute coronary syndromes, heart failure and chronic kidney disease. World J Cardiol 2015; 7: 397-403
3. Hirsh BJ, Copeland-Halperin RS and Halperin JL. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. J Am Coll Cardiol 2015; 65: 2239-2251
4. Poudel P, Xu Y, Cui Z, Sharma D, Tian B and Paudel S. Atrial fibrillation: recent advances in understanding the role of microRNAs in atrial remodeling with an electrophysiological overview. Cardiology 2015; 131: 58-67
5. Bunch TJ and Day JD. Adverse Remodeling of the Left Atrium in Patients with Atrial Fibrillation: When Is the Tipping Point in Which Structural Changes Become Permanent? J Cardiovasc Electrophysiol 2015; 26: 606-607
6. Wu H, Xie J, Li GN, Chen QH, Li R, Zhang XL, Kang LN and Xu B. Possible involvement of TGF-beta/periostin in fibrosis of right atrial appendages in patients with atrial fibrillation. Int J Clin Exp Pathol 2015; 8: 6859-6869
7. Zhang L, Huang B, Scherlag BJ, Ritchey JW, Embi AA, Hu J, Hou Y and Po SS. Structural changes in the progression of atrial fibrillation: potential role of glycogen and fibrosis as perpetuating factors. Int J Clin Exp Pathol 2015; 8: 1712-1718
8. Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H and Dhein S. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 2004; 90: 400-405
9. Habegger KM, Stemmer K, Cheng C, Muller TD, Heppner KM, Ottaway N, Holland J, Hembree JL, Smiley D, Gelfanov V, Krishna R, Arafat AM, Konkar A, Belli S, Kapps M, Woods SC, Hofmann SM, D'Alessio D, Pfluger PT, Perez-Tilve D, Seeley RJ, Konishi M, Itoh N, Kharitonenkov A, Spranger J, DiMarchi RD and Tschop MH. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013; 62: 1453-1463
10. Angelin B, Larsson TE and Rudling M. Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab 2012; 16: 693-705
11. Zhu W, Wang C, Liu L, Li Y, Li X, Cai J and Wang H. Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo. Can J Physiol Pharmacol 2014; 92: 927-935
12. Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, Lu Z, Gao M, Bao Y and Jia W. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol 2013; 12: 124
13. Han X, Chen C, Cheng G, Xie C, Yang M, Shou X and Sun C. Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients. Cytokine 2015; 73: 176-180
14. Dzeshka MS, Lip GY, Snezhitskiy V and Shantsila E. Cardiac fibrosis in patients with atrial fibrillation: mechanisms and clinical implications. J Am Coll Cardiol 2015; 66: 943-959
15. Akoum N and Marrouche N. Assessment and impact of cardiac fibrosis on atrial fibrillation. Curr Cardiol Rep 2014; 16: 518
16. Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XH, Nattel S and Dobrev D. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 2014; 129: 145-156
17. Andrade J, Khairy P, Dobrev D and Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 2014; 114: 1453-1468
18. Kallergis EM, Goudis CA and Vardas PE. Atrial fibrillation: a progressive atrial myopathy or a distinct disease? Int J Cardiol 2014; 171: 126-133
19. Takahashi N, Kume O, Wakisaka O, Fukunaga N, Teshima Y, Hara M and Saikawa T. Novel strategy to prevent atrial fibrosis and fibrillation. Circ J 2012; 76: 2318-2326
20. Ohta H, Konishi M and Itoh N. FGF10 and FGF21 as regulators in adipocyte development and metabolism. Endocr Metab Immune Disord Drug Targets 2011; 11: 302-309
21. Cuevas-Ramos D, Aguilar-Salinas CA and Gomez-Perez FJ. Metabolic actions of fibroblast growth factor 21. Curr Opin Pediatr 2012; 24: 523-529
22. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR and Shanafelt AB. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635
23. Kim KH and Lee MS. FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases. Diabetes Metab J 2014; 38: 245-251
24. Liu J, Xu Y, Hu Y and Wang G. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism 2015; 64: 380-390
25. Al-Rawahi M, Proietti R and Thanassoulis G. Pericardial fat and atrial fibrillation: Epidemiology, mechanisms and interventions. Int J Cardiol 2015; 195: 98-103
26. Hatem SN and Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 2014; 102: 205-213
27. Liu WY, Huang S, Shi KQ, Zhao CC, Chen LL, Braddock M, Chen YP, Feng WK and Zheng MH. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opin Ther Targets 2014; 18: 1305-1313